<DOC>
	<DOCNO>NCT00959036</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ATN-103 administer subject active rheumatoid arthritis compare placebo . All subject must stable dose route methotrexate .</brief_summary>
	<brief_title>Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Clinical diagnosis active rheumatoid arthritis stable background methotrexate ( 7.525 mg weekly ) . Any significant health problem rheumatoid arthritis Any clinically significant laboratory abnormality Any prior use B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>